Adcock Ingram intends to continue seeking partnership deals with multinational firms, after failing to complete two significant acquisitions during its financial year ended 30 June 2022.

South Africa’s Adcock Ingram gave a sprawling update of its operations for the first half of its financial year ending in June 2022, which saw a rise in sales but a decline in profit for its Prescription business.

South African firm Adcock Ingram has described the launch of Celltrion’s Remsima (infliximab) biosimilar as “a really good step for us,” as it saw volumes plunge for its Prescription business during its financial year ended 30 June.

Adcock has made slight progress despite the effect of the current economic climate in South Africa on consumer spending and behavior.